{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":3,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"61eb7b31e46f","filters":{"venue":"Biological Products Prevention Diagnosis Treatment"}},"results":[{"id":"W4362674372","doi":"10.30895/2221-996x-2023-23-1-26-41","title":"Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain","year":2023,"lang":"en","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Poxvirus research and outbreaks","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Vaccinia; Smallpox; myalgia; Chills; Smallpox vaccine; Adverse effect; Vaccination; Modified vaccinia Ankara; Immunogenicity; Virology; Attenuated vaccine; Immunology; Surgery; Internal medicine; Immune system","authors":[{"name":"L. F. Stovba","is_ca":false},{"name":"O. V. Chukhralya","is_ca":false},{"name":"Н. К. Черникова","is_ca":false},{"name":"A. L. Khmelev","is_ca":false},{"name":"С. В. Борисевич","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08164719609911085,"gpt":0.3061261695840588,"spread":0.2244789734849479,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001100052,0.0002745999,0.0003724362,0.0002222972,0.0001513127,0.0004470859,0.0001566365,0.0004561943,0.0007378064],"category_scores_gemma":[0.001630828,0.0001071928,0.0005794499,0.0001772704,0.0003062387,0.0003337245,0.0001670989,0.0005598174,0.0001831592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003388239,"about_ca_system_score_gemma":0.0003621878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002790132,"about_ca_topic_score_gemma":0.0001166643,"domain_scores_codex":[0.9993775,0.0002163467,0.00006084175,0.00008271061,0.0002113474,0.00005115996],"domain_scores_gemma":[0.9988353,0.0004006564,0.0003800977,0.00009725273,0.0002291731,0.00005761276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04281841,0.008076414,0.2048777,0.002566258,0.0007371672,0.001798733,0.002116822,0.004886706,0.3241843,0.0008956796,0.001337536,0.4057043],"study_design_scores_gemma":[0.001254759,0.3325749,0.4349268,0.0002834466,0.001237246,0.00693261,0.0007083411,0.004257682,0.1939377,0.000822866,0.02298182,0.00008177524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938916,0.004122055,0.0006157923,0.00008069199,0.0000330318,0.00005851909,0.0001208204,0.000007570546,0.001069838],"genre_scores_gemma":[0.9982812,0.0008067979,0.0002138415,0.00004628765,0.00003211402,0.00002035366,0.000175854,0.000002383012,0.0004210111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001100052,"threshold_uncertainty_score":0.005817711,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","authors":[{"name":"А. А. Солдатов","is_ca":false},{"name":"Ж. И. Авдеева","is_ca":false},{"name":"Ю. В. Олефир","is_ca":false},{"name":"В. А. Меркулов","is_ca":false},{"name":"В. П. Бондарев","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.105695995460469,"gpt":0.3372912321613004,"spread":0.2315952367008313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001457958,0.0004889398,0.0003673431,0.001660706,0.001399385,0.002202966,0.0005348228,0.001846965,0.0297105],"category_scores_gemma":[0.002220161,0.0007816509,0.00071393,0.001101143,0.001369368,0.001166981,0.0009445093,0.002372422,0.01868257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001195114,"about_ca_system_score_gemma":0.001794148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004077377,"about_ca_topic_score_gemma":0.004947756,"domain_scores_codex":[0.9984832,0.0001959471,0.0001054878,0.0002518447,0.000831292,0.0001322766],"domain_scores_gemma":[0.9990086,0.0002546216,0.0001796664,0.0001619188,0.0003197461,0.0000754409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003593036,0.0001687732,0.001341526,0.001614172,0.00006739538,0.001824789,0.001356449,0.0009839108,0.1623938,0.2538715,0.03226573,0.5437527],"study_design_scores_gemma":[0.00004286287,0.0001202391,0.00229449,0.0001515217,0.00005559975,0.001685336,0.0002144798,0.0004713516,0.04756766,0.01648889,0.9308296,0.00007780531],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.05894608,0.08695616,0.1872747,0.0133834,0.008911226,0.0009402064,0.002727996,0.002094366,0.6387658],"genre_scores_gemma":[0.4523464,0.05020865,0.1859086,0.002703141,0.001576788,0.001394118,0.001158365,0.0007682373,0.3039357],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0297105,"threshold_uncertainty_score":0.09939152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2888948683","doi":"","title":"Трансплантация фекальной микробиоты: возможные терапевтические подходы и вопросы правового регулирования","year":2015,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Fecal bacteriotherapy; Clostridium difficile; Diarrhea; Feces; Medicine; Disease; Intensive care medicine; Microbiology; Immunology; Biology; Gastroenterology; Pathology; Antibiotics","authors":[{"name":"А Н Васильев","is_ca":false},{"name":"Д. В. Горячев","is_ca":false},{"name":"E.V. Gavrishina","is_ca":false},{"name":"Р. Р. Ниязов","is_ca":false},{"name":"Ю А Селиверстов","is_ca":false},{"name":"А. В. Дигтярь","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2152733699083489,"gpt":0.378070391677353,"spread":0.162797021769004,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007193517,0.0003179489,0.0002999055,0.00201644,0.001273664,0.002568671,0.0003466648,0.0007378627,0.01385158],"category_scores_gemma":[0.001415755,0.0004715243,0.0003216471,0.00170711,0.001693643,0.001217816,0.0008667297,0.001241841,0.004845752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001127818,"about_ca_system_score_gemma":0.001869418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00379917,"about_ca_topic_score_gemma":0.006299205,"domain_scores_codex":[0.9993672,0.0001117575,0.00003237691,0.00009225127,0.0003225821,0.00007380214],"domain_scores_gemma":[0.9993342,0.0001673351,0.0001321782,0.0000858149,0.0001914072,0.00008899126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002182173,0.0001109849,0.003266353,0.0008202191,0.00005071731,0.001733326,0.002260351,0.001200637,0.05886531,0.3954308,0.01409919,0.5219439],"study_design_scores_gemma":[0.00003047856,0.0001196496,0.006476759,0.0002505981,0.0000507524,0.001968636,0.00102033,0.0006822995,0.02070363,0.06146747,0.9071494,0.00008006846],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"review","genre_scores_codex":[0.1607779,0.1830022,0.1168949,0.01564934,0.005127441,0.0002884828,0.001135251,0.0006164817,0.516508],"genre_scores_gemma":[0.7303828,0.08029398,0.0838943,0.0007099648,0.0009276675,0.0003343178,0.0003291887,0.0002247573,0.1029031],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01385158,"threshold_uncertainty_score":0.04633814,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}